EP4653047A3 - Mifepristone destinée à être utilisée pour améliorer la sensibilité à l'insuline - Google Patents

Mifepristone destinée à être utilisée pour améliorer la sensibilité à l'insuline

Info

Publication number
EP4653047A3
EP4653047A3 EP25207614.6A EP25207614A EP4653047A3 EP 4653047 A3 EP4653047 A3 EP 4653047A3 EP 25207614 A EP25207614 A EP 25207614A EP 4653047 A3 EP4653047 A3 EP 4653047A3
Authority
EP
European Patent Office
Prior art keywords
insulin sensitivity
mifepristone
improving insulin
disorder
hypothalamic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP25207614.6A
Other languages
German (de)
English (en)
Other versions
EP4653047A2 (fr
Inventor
Lynnette K. NIEMAN
André Ulmann
Arnold L. Newman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP4653047A2 publication Critical patent/EP4653047A2/fr
Publication of EP4653047A3 publication Critical patent/EP4653047A3/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
EP25207614.6A 2019-03-18 2020-03-09 Mifepristone destinée à être utilisée pour améliorer la sensibilité à l'insuline Pending EP4653047A3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962919496P 2019-03-18 2019-03-18
PCT/US2020/000009 WO2020190351A1 (fr) 2019-03-18 2020-03-09 Procédé permettant d'améliorer la sensibilité à l'insuline
EP20774479.8A EP3941460B1 (fr) 2019-03-18 2020-03-09 Mifepristone pour utilisation dans l'amélioration de la sensibilité à l'insuline

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP20774479.8A Division EP3941460B1 (fr) 2019-03-18 2020-03-09 Mifepristone pour utilisation dans l'amélioration de la sensibilité à l'insuline

Publications (2)

Publication Number Publication Date
EP4653047A2 EP4653047A2 (fr) 2025-11-26
EP4653047A3 true EP4653047A3 (fr) 2026-02-18

Family

ID=72521042

Family Applications (2)

Application Number Title Priority Date Filing Date
EP25207614.6A Pending EP4653047A3 (fr) 2019-03-18 2020-03-09 Mifepristone destinée à être utilisée pour améliorer la sensibilité à l'insuline
EP20774479.8A Active EP3941460B1 (fr) 2019-03-18 2020-03-09 Mifepristone pour utilisation dans l'amélioration de la sensibilité à l'insuline

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20774479.8A Active EP3941460B1 (fr) 2019-03-18 2020-03-09 Mifepristone pour utilisation dans l'amélioration de la sensibilité à l'insuline

Country Status (5)

Country Link
US (2) US20220288091A1 (fr)
EP (2) EP4653047A3 (fr)
KR (1) KR20210153056A (fr)
AU (1) AU2020239920A1 (fr)
WO (1) WO2020190351A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7196201B2 (ja) 2018-06-04 2022-12-26 コーセプト セラピューティクス， インコーポレイテッド ピリミジンシクロヘキセニル糖質コルチコイドレセプター調節因子
KR102911885B1 (ko) * 2020-05-06 2026-01-12 코어셉트 쎄라퓨틱스 인코포레이티드 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제의 다형체
JP7474869B2 (ja) 2020-05-06 2024-04-25 コーセプト セラピューティクス， インコーポレイテッド ピリミジンシクロヘキシルグルココルチコイド受容体モジュレーターの製剤
WO2022134033A1 (fr) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Procédés de préparation de modulateurs du récepteur des glucocorticoïdes d'azadécaline fusionnée hétéroaryle-cétone
CN114907349A (zh) * 2021-02-10 2022-08-16 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
KR20250073629A (ko) 2022-10-06 2025-05-27 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제의 제형
EP4716536A1 (fr) * 2023-05-22 2026-04-01 Corcept Therapeutics Incorporated Méthodes de traitement des tumeurs de la glande surrénale
WO2025174742A1 (fr) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated Administration concomitante de miricorilant avec des inhibiteurs de cyp2c19
WO2025174745A1 (fr) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated Traitement de miricorilant pour stéatoses hépatiques et ses effets sur la teneur en graisse hépatique, acides gras, acylglycérols et acides biliaires secondaires

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073548A (en) * 1988-06-23 1991-12-17 Research Triangle Institute 11 β-substituted progesterone analogs
WO2001052833A1 (fr) * 2000-01-21 2001-07-26 Cortendo Ab Compositions permettant la liberation d'antagoniste de cortisol
US20020147336A1 (en) * 1999-04-30 2002-10-10 Dow Robert L. Glucocorticoid receptor modulators
WO2003009853A1 (fr) * 2001-07-23 2003-02-06 Corcept Therapeutics, Inc. Methodes de prevention de la prise de poids induite par les antipsychotiques
US20090088425A1 (en) * 2007-09-27 2009-04-02 Jacques Bailly Glucocorticoid receptor antagonists
CN102204918A (zh) * 2011-03-03 2011-10-05 厦门大学 一种PPARγ激动剂的类固醇化合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296206A (en) 1980-04-30 1981-10-20 United States Of America Irreversible anti-glucocorticoids
US4978657A (en) 1981-01-09 1990-12-18 Roussel Uclaf Novel 11β-substituted-19-nor-steroids
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2639045B2 (fr) 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3761308D1 (de) 1986-07-23 1990-02-08 Akzo Nv 18-phenylestrane-derivate.
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US4861763A (en) 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
US4921638A (en) 1986-11-05 1990-05-01 The Upjohn Company 17β-cyano-9α,17α-dihydroxyandrost-4-en-3-one
FR2618783B1 (fr) 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6051573A (en) 1994-06-28 2000-04-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists
US5696127A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
IT1279004B1 (it) 1995-03-10 1997-12-02 Ausimont Spa Composizioni ad alto secco a base di fluoropolieteri
IL118974A (en) 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
EP0903146A1 (fr) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19oxidoprogestérone (21-OH-60P) en tant qu'antiglucocorticoide
AU747956B2 (en) 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
US6166013A (en) * 1998-07-30 2000-12-26 Abbott Laboratories Glucocortiocoid-selective agents
EP1113007A1 (fr) 1999-12-24 2001-07-04 Pfizer Inc. Composés de tétrahydroisoquinoline comme agonistes/antagonistes d'oestrogène
IL180679A0 (en) 2000-10-27 2009-02-11 Pfizer Prod Inc Process for the preparation of non-steroidal glucocorticoid receptor modulators
DE60232956D1 (de) 2001-03-23 2009-08-27 Corcept Therapeutics Inc Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
SI1521733T1 (sl) 2002-07-08 2014-10-30 Pfizer Products Inc. Modulatorji glukokortikoidnega receptorja
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
US20050080061A1 (en) * 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
CA2558899C (fr) 2004-03-09 2013-02-05 Corcept Therapeutics, Inc. Modulateurs de recepteurs glucocorticoides d'azadecaline a cycles accoles
WO2010081015A1 (fr) 2009-01-09 2010-07-15 The Regents Of The University Of California Découverte de modulateurs sélectifs du récepteur de glucocorticoïde par criblage multiplex de gènes rapporteurs
US20120028358A1 (en) * 2010-06-28 2012-02-02 University Of South Alabama Method for increasing retroviral infectivity
RU2598842C2 (ru) * 2011-01-20 2016-09-27 Мерк Шарп Энд Домэ Корп. Антагонисты рецептора минералокортикоидов
US10919929B2 (en) 2013-12-11 2021-02-16 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
CN111557942B (zh) 2014-10-15 2023-10-03 科赛普特治疗学股份有限公司 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗
JP6765443B2 (ja) 2016-01-19 2020-10-07 コーセプト セラピューティクス， インコーポレイテッド 異所性クッシング症候群の鑑別診断

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073548A (en) * 1988-06-23 1991-12-17 Research Triangle Institute 11 β-substituted progesterone analogs
US20020147336A1 (en) * 1999-04-30 2002-10-10 Dow Robert L. Glucocorticoid receptor modulators
WO2001052833A1 (fr) * 2000-01-21 2001-07-26 Cortendo Ab Compositions permettant la liberation d'antagoniste de cortisol
WO2003009853A1 (fr) * 2001-07-23 2003-02-06 Corcept Therapeutics, Inc. Methodes de prevention de la prise de poids induite par les antipsychotiques
US20090088425A1 (en) * 2007-09-27 2009-04-02 Jacques Bailly Glucocorticoid receptor antagonists
CN102204918A (zh) * 2011-03-03 2011-10-05 厦门大学 一种PPARγ激动剂的类固醇化合物及其用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "History of Changes for Study: NCT03052400 Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus", CLINICALTRIALS.GOV ARCHIVE, 1 January 2017 (2017-01-01), pages 1 - 7, XP055981665, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/history/NCT03052400?V_2=View#StudyPageTop> [retrieved on 20221115] *
CHU J W ET AL: "Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486)", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US, vol. 86, no. 8, 1 August 2001 (2001-08-01), pages 3568 - 3573, XP002410091, ISSN: 0021-972X, DOI: 10.1210/JC.86.8.3568 *
CLARK ROBIN: "Glucocorticoid Receptor Antagonists", CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 8, no. 9, 1 June 2008 (2008-06-01), NL, pages 813 - 838, XP093138635, ISSN: 1568-0266, Retrieved from the Internet <URL:https://www.eurekaselect.com/article/27705> DOI: 10.2174/156802608784535011 *
DEBONO MIGUEL ET AL: "Mifepristone Reduces Insulin Resistance in Patient Volunteers with Adrenal Incidentalomas That Secrete Low Levels of Cortisol: A Pilot Study", vol. 8, no. 4, 1 January 2013 (2013-01-01), pages e60984, XP055981535, Retrieved from the Internet <URL:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0060984&type=printable> DOI: 10.1371/journal.pone.0060984 *
GUBBI SRIRAM ET AL: "Mifepristone Improves Adipose Tissue Insulin Sensitivity in Insulin Resistant Individuals", vol. 106, no. 5, 23 April 2021 (2021-04-23), US, pages 1501 - 1515, XP055981608, ISSN: 0021-972X, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063260/> DOI: 10.1210/clinem/dgab046 *
YOSUP REW ET AL: "Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, no. 17, 9 August 2018 (2018-08-09), US, pages 7767 - 7784, XP055605922, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b00743 *

Also Published As

Publication number Publication date
EP3941460B1 (fr) 2025-10-15
WO2020190351A9 (fr) 2021-03-11
EP3941460A1 (fr) 2022-01-26
EP4653047A2 (fr) 2025-11-26
EP3941460C0 (fr) 2025-10-15
AU2020239920A1 (en) 2021-11-04
KR20210153056A (ko) 2021-12-16
US20250281504A1 (en) 2025-09-11
EP3941460A4 (fr) 2022-12-28
WO2020190351A1 (fr) 2020-09-24
US20220288091A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
EP4653047A3 (fr) Mifepristone destinée à être utilisée pour améliorer la sensibilité à l&#39;insuline
Leistner et al. How to measure glucocorticoid receptor’s sensitivity in patients with stress-related psychiatric disorders
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
BRPI0512674A (pt) compostos e composições como moduladores de receptores nucleares de hormÈnio esteróide
SG11202009839PA (en) Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
US2275315A (en) Means for attaching fragile bodies to a support
WO2018191548A3 (fr) Anticorps antagonistes du facteur d du complément et leurs conjugués
DK1408981T3 (da) Fremgangsmåder til forebyggelse af vægtforögelse som fölge af antipsykotiske midler
MA40106A1 (fr) Anticorps anti-il-25 et leurs utilisations
SG11201908659RA (en) Chimeric antigen receptor
MX383353B (es) Uso de antagonistas de receptores de glucocorticoides en combinacion con glucocorticoides para tratar la insuficiencia adrenal.
HRP20241046T1 (hr) Antagonisti crf1 receptora za liječenje kongenitalne adrenalne hiperplazije
EP4019323A4 (fr) Siège à gravité nulle et véhicule comprenant celui-ci
KR20170017605A (ko) 로드 셀이 설치된 사일로
CL2008001672A1 (es) Compuestos derivados de isoindol, antagonistas del receptor de urotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hipertension vascular, insuficiencia cardiaca, trastornos del sistema nervioso central.
IL290138A (en) Methods of treating diseases associated with elevated levels of antibodies that interact with the nmda receptor
Sivik et al. Progesterone and levonorgestrel regulate expression of 17βHSD-enzymes in progesterone receptor positive breast cancer cell line T47D
EP4541367A3 (fr) Traitement d&#39;états inflammatoires par administration d&#39;une protéine de fusion antagoniste du récepteur d&#39;interleukine-1
Jibladze et al. Normal forms of nilpotent elements in semisimple Lie algebras
Dahlqvist et al. Is Adrenal insufficiency a rare disease?
Engel et al. (2018-2019) Assembly Resolution 1: In Support of Thanking Dean Lilly for Offering to Fully Fund the UText Initiative
Ляшенко et al. Program of educational discipline of piano for students of the first form.
Han et al. On a family of triangle groups in complex hyperbolic geometry
FR3086165B1 (fr) Dispositif de reglage de l’inclinaison de l’assise d’un siege d’un fauteuil roulant et fauteuil roulant comprenant un tel dispositif
Liu The Dieck-Temperley-Lieb algebras of type B and C in Brauer algebras

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3941460

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0003100000

Ipc: A61K0031567000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/567 20060101AFI20260112BHEP

Ipc: A61K 31/4745 20060101ALI20260112BHEP

Ipc: A61K 31/513 20060101ALI20260112BHEP

Ipc: A61K 31/57 20060101ALI20260112BHEP

Ipc: A61K 31/585 20060101ALI20260112BHEP

Ipc: A61K 31/365 20060101ALI20260112BHEP

Ipc: A61K 45/06 20060101ALI20260112BHEP

Ipc: A61P 3/04 20060101ALI20260112BHEP

Ipc: A61P 3/06 20060101ALI20260112BHEP

Ipc: A61P 3/08 20060101ALI20260112BHEP

Ipc: A61P 3/10 20060101ALI20260112BHEP